Polskie Archiwum Medycyny Wewnętrznej
-
Pol. Arch. Med. Wewn. · Oct 2022
Editorial CommentCOVID‑19: different waves and different outcomes.
-
Pol. Arch. Med. Wewn. · Oct 2022
Comparison between COVID-19 outcomes in the first three waves of pandemic: a reference hospital report.
The course of consecutive COVID‑19 waves was influenced by medical and organizational factors. ⋯ We identified differences in patients' clinical characteristics and outcomes between consecutive pandemic waves, which probably reflect changes in terms of COVID‑19 isolation policy, hospitalization and treatment indications, and treatment strategies.
-
Pol. Arch. Med. Wewn. · Oct 2022
SGLT-2 inhibitors in obesity and its associated cardiometabolic disorders: where do we stand?
As the tide of obesity and its complications are on the rise, there is an urgent need for new drugs with weight‑lowering and beneficial metabolic properties. Obesity‑related disorders, such as metabolic syndrome, prediabetes, type 2 diabetes (T2D), cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD) make this need more than mandatory. Sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitors (empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin) are the latest class of agents to receive approval for the treatment of T2D. ⋯ Very few reviews in the literature have holistically appraised the therapeutic potential of SGLT‑2 inhibitors in obesity and its associated complications. Herein, we summarize the currently available evidence regarding the effects of drugs of this class on body adiposity, together with considerations on their potential use as weight loss agents. Furthermore, we attempt to overview their actions and future perspectives of their use with respect to a range of obesity‑related disorders, which include cardiovascular, renal, and ovarian dysfunctions, as well as NAFLD and malignancy.
-
Pol. Arch. Med. Wewn. · Oct 2022
Unravelling the relationship between serum 25-hydroxyvitamin D levels and trabecular bone score in U.S. adults.
Trabecular bone score (TBS) is a novel way for clinicians to evaluate bone quality. It is directly associated with the mechanical strength of bones and helps predict fractures. Vitamin D, a secosteroid that enhances calcium absorption, is commonly used to strengthen the skeletal system. ⋯ Our study shows that low serum levels of 25(OH)D may decrease the TBS, which represents the skeletal microarchitecture and is a fracture risk factor in individuals with normal T‑scores.